The FDA recently launched the Digital Health Center of Excellence to further the “Agency’s overarching dedication to the advancement of digital health technology.” What technologies will and won’t the new center monitor?
Will investments in digital health continue? Does capitation lower costs? How do patient reviews improve practices? Find the answers to these questions and more in The Rundown!
Is diet linked to dementia risk? What changes were made to healthcare in President Trump’s budget proposal? Why are pharmacy benefit managers testifying before the Senate? Find the answers to these questions and more in The Rundown!
After 35 days, the longest government shutdown in American history has ended — at least temporarily. From unpaid medical debt to skipped food inspections to unapproved generic drugs, the closure seriously impacted the healthcare industry. Learn how and find out what this means for the future.
What does the FDA’s clearance of Apple Watches mean for wearables? What’s the true cost of healthcare illiteracy? Can aspirin regimens do more harm than good? Find the answers to these questions and more in The Rundown, our weekly digest of healthcare’s most important issues!
Who is the latest addition to Amazon’s healthcare venture? What Nobel Prize-winning pharmaceutical will hit the market and what’s the price tag? Why has NYU decided to pay for med school students’ tuition? All this and more in The Rundown, your weekly digest of healthcare’s most important issues!
Busy provider looking for healthcare news? Check out The Rundown. Inequality in Female Salaries and Leadership Within Healthcare A new survey from Rock Health suggests women represent just 22 percent of Fortune 500 healthcare executives, a third of all executives at hospitals, and only 10–12 percent of CEOs and venture-capital partners at funded digital-health …
Busy provider looking for healthcare news? Check out The Rundown. FDA Await DEA Decision on Marijuana Pharmaceutical The US Food and Drug Administration (FDA) approved the first cannabidiol (CBD) for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. Approval of the marijuana-derived drug, Epidiolex, followed three randomized, placebo-controlled studies on …